Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 12 11 2018
revised: 13 05 2019
accepted: 15 05 2019
pubmed: 18 7 2019
medline: 16 5 2020
entrez: 18 7 2019
Statut: ppublish

Résumé

Mutations in lysosomal genes increase the risk of neurodegenerative diseases, as is the case for Parkinson's disease. Here, we found that pathogenic and protective mutations in arylsulfatase A (ARSA), a gene responsible for metachromatic leukodystrophy, a lysosomal storage disorder, are linked to Parkinson's disease. Plasma ARSA protein levels were changed in Parkinson's disease patients. ARSA deficiency caused increases in α-synuclein aggregation and secretion, and increases in α-synuclein propagation in cells and nematodes. Despite being a lysosomal protein, ARSA directly interacts with α-synuclein in the cytosol. The interaction was more extensive with protective ARSA variant and less with pathogenic ARSA variant than wild-type. ARSA inhibited the in vitro fibrillation of α-synuclein in a dose-dependent manner. Ectopic expression of ARSA reversed the α-synuclein phenotypes in both cell and fly models of synucleinopathy, the effects correlating with the extent of the physical interaction between these molecules. Collectively, these results suggest that ARSA is a genetic modifier of Parkinson's disease pathogenesis, acting as a molecular chaperone for α-synuclein.

Identifiants

pubmed: 31312839
pii: 5532496
doi: 10.1093/brain/awz205
doi:

Substances chimiques

Caenorhabditis elegans Proteins 0
Drosophila Proteins 0
Molecular Chaperones 0
Recombinant Proteins 0
alpha-Synuclein 0
Cerebroside-Sulfatase EC 3.1.6.8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2845-2859

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Jun Sung Lee (JS)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Kazuaki Kanai (K)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Mari Suzuki (M)

Diabetic Neuropathy Project, Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Woojin S Kim (WS)

Brain and Mind Centre, Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia.

Han Soo Yoo (HS)

Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.

YuHong Fu (Y)

Brain and Mind Centre, Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia.

Dong-Kyu Kim (DK)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Byung Chul Jung (BC)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Minsun Choi (M)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Kyu Won Oh (KW)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Yuanzhe Li (Y)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Mitsuyoshi Nakatani (M)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Tomoko Nakazato (T)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Satoko Sekimoto (S)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Manabu Funayama (M)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Hiroyo Yoshino (H)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Shin-Ichiro Kubo (SI)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Kenya Nishioka (K)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Ryusuke Sakai (R)

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Morio Ueyama (M)

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Hideki Mochizuki (H)

Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

He-Jin Lee (HJ)

Departmen of Anatomy, School of Medicine, Konkuk University, Seoul, Korea.

Sergio Pablo Sardi (SP)

Genzyme, a Sanofi Company, Framingham, Massachusetts, USA.

Glenda M Halliday (GM)

Brain and Mind Centre, Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia.

Yoshitaka Nagai (Y)

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Phil Hyu Lee (PH)

Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.

Nobutaka Hattori (N)

Department of Neurology, Juntendo University, School of Medicine, Tokyo 113-8421, Japan.

Seung-Jae Lee (SJ)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH